1. Home
  2. TNET vs MLYS Comparison

TNET vs MLYS Comparison

Compare TNET & MLYS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo TriNet Group Inc.

TNET

TriNet Group Inc.

HOLD

Current Price

$45.54

Market Cap

2.2B

ML Signal

HOLD

Logo Mineralys Therapeutics Inc.

MLYS

Mineralys Therapeutics Inc.

HOLD

Current Price

$25.03

Market Cap

2.1B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
TNET
MLYS
Founded
1988
2019
Country
United States
United States
Employees
2700
N/A
Industry
Business Services
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
2.2B
2.1B
IPO Year
2000
2023

Fundamental Metrics

Financial Performance
Metric
TNET
MLYS
Price
$45.54
$25.03
Analyst Decision
Hold
Strong Buy
Analyst Count
5
7
Target Price
$65.80
$48.67
AVG Volume (30 Days)
342.8K
1.9M
Earning Date
04-30-2026
05-06-2026
Dividend Yield
2.57%
N/A
EPS Growth
N/A
37.43
EPS
1.90
N/A
Revenue
$5,010,000,000.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
$3.30
N/A
P/E Ratio
$24.51
N/A
Revenue Growth
N/A
N/A
52 Week Low
$33.67
$12.59
52 Week High
$76.09
$47.65

Technical Indicators

Market Signals
Indicator
TNET
MLYS
Relative Strength Index (RSI) 50.50 44.59
Support Level $34.47 $22.36
Resistance Level $45.62 $31.29
Average True Range (ATR) 1.96 1.43
MACD -0.25 -0.22
Stochastic Oscillator 5.05 28.15

Price Performance

Historical Comparison
TNET
MLYS

About TNET TriNet Group Inc.

Trinet Group Inc provides human resources solutions for small and medium-sized businesses through technology-enabled services. Its offerings include human capital expertise, employee benefits such as health insurance and retirement plans, payroll and payroll tax administration, risk mitigation, and compliance consulting. The company provides its services through professional employer organization (PEO) services delivered via a co-employment model, as well as administrative services organization (ASO) offerings. The majority of the company's revenue is derived from the insurance-related billings and administrative fees collected from PEO clients.

About MLYS Mineralys Therapeutics Inc.

Mineralys Therapeutics Inc is a biopharmaceutical company focused on developing medicines to target diseases driven by dysregulated aldosterone. The Company's product candidate, lorundrostat, is a proprietary, orally administered, aldosterone synthase inhibitor that the Company is developing for the treatment of cardiorenal conditions affected by dysregulated aldosterone, including hypertension and related comorbidities, such as chronic kidney disease and obstructive sleep apnea. Its product candidate, lorundrostat, is a proprietary, orally administered, selective ASI that is designed to reduce aldosterone levels by inhibiting CYP11B2, the enzyme responsible for producing the hormone.

Share on Social Networks: